Copd Management Therapeutics
1. Modeyso patent expiration
Treatment: Method of treating adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an h3 k27m mutation with progressive disease following prior therapy
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9265765 | CHIMERIX | 7-Benzyl-10-(2-Methylbenzyl)-2,6,7,8,9,10-Hexahydroimidazo[1,2-A]Pyrido[4,3-D]Pyrimidin-5(3H)-One, Salts Thereof And Methods Of Using The Same In Combination Therapy |
Jul, 2034
(8 years from now) | |
| US11976068 | CHIMERIX | 7-Benzyl-4-(2-Methylbenzyl)-2,4,6,7,8,9-Hexahydroimidazo [1,2-A]Pyrido[3,4-E]Pyrimidin-5(1H)-One, Analogs Thereof, And Salts Thereof And Methods For Their Use In Therapy |
Mar, 2036
(10 years from now) | |
| USRE46290 | CHIMERIX | NA |
Apr, 2032
(6 years from now) | |
| US10369154 | CHIMERIX | Imipridones For Gliomas |
Jan, 2037
(10 years from now) | |
| US12102639 | CHIMERIX | Imipridones For Gliomas |
Jan, 2037
(10 years from now) | |
| US9629842 | CHIMERIX | Small Molecule Trail Gene Induction By Normal And Tumor Cells As An Anticancer Therapy |
Apr, 2032
(6 years from now) | |
| US10172862 | CHIMERIX | Imipridones For Gliomas |
Jan, 2037
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2030 |
Drugs and Companies using DORDAVIPRONE HYDROCHLORIDE ingredient
NCE-1 date: 06 August, 2029
Market Authorisation Date: 06 August, 2025
Dosage: CAPSULE
More Information on Dosage
MODEYSO family patents
2. Ohtuvayre patent expiration
Treatment: For the maintenance treatment of chronic obstructive pulmonary disease (copd) in adult patients
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9062047 | VERONA | Crystalline form of pyrimido[6,1-A] isoquinolin-4-one compound |
Aug, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12409180 | VERONA | Formulation Production Process |
Feb, 2043
(17 years from now) | |
| US9956171 | VERONA | Liquid inhalation formulation comprising RPL554 |
Sep, 2035
(9 years from now) | |
| US12251384 | VERONA | Particulate composition |
Jun, 2044
(18 years from now) | |
| US10945950 | VERONA | Liquid inhalation formulation comprising RPL554 |
Sep, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 26, 2029 |
Drugs and Companies using ENSIFENTRINE ingredient
NCE-1 date: 26 June, 2028
Market Authorisation Date: 26 June, 2024
Dosage: SUSPENSION
More Information on Dosage
OHTUVAYRE family patents